Patents Assigned to Selexys Pharmaceuticals, Inc.
  • Methods of treating sickle cell disease with anti-P-selectin antibodies
    Patent number: 9556266
    Abstract: The invention features antibodies, e.g., chimeric and humanized antibodies, that recognize (i.e., bind) P-selectin. The P-selectin antibodies prevent P-selectin from binding to its cognate receptor. The P-selectin antibodies can be used to treat inflammatory and thrombotic conditions, e.g., sickle cell disease, pain crisis associated with sickle cell disease, deep vein thrombosis, asthma, rheumatoid arthritis, psoriasis, and ischemia reperfusion injury in a patient in need thereof.
    Type: Grant
    Filed: February 1, 2013
    Date of Patent: January 31, 2017
    Assignees: Selexys Pharmaceuticals, Inc., Oklahoma Medical Research Foundation
    Inventors: Rodger P. McEver, Richard Alvarez, Ziad Kawar